All practice questions

4736 questions

Question 4541Question →

A 72-year-old retired accountant is brought to the outpatient clinic by his son due to progressive memory decline over the past 14 months. The son reports that the patient frequently forgets recent conversations, misplaces household items, and recently struggled to balance his checkbook, a task he previously managed with ease. The patient has a medical history of essential hypertension and benign prostatic hyperplasia. Current medications include lisinopril and tamsulosin. Vital signs are within normal limits. On physical examination, there are no focal neurological deficits, and his gait is normal. The patient scores 22/30 on a standardized cognitive assessment.

According to current guidelines, which of the following investigations are indicated as part of the initial concurrent diagnostic workup to evaluate for reversible causes of this patient's cognitive decline? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Serum vitamin B12 level; Serum thyroid-stimulating hormone (TSH) level

Answer

The correct tests to include in the initial workup are the Serum vitamin B12 level and the Serum thyroid-stimulating hormone (TSH) level.
The initial diagnostic workup for a patient presenting with new-onset progressive cognitive impairment requires screening for common and potentially reversible metabolic causes. Current guidelines mandate checking a serum vitamin B12 level and a thyroid-stimulating hormone (TSH) level in all such patients. Identifying these deficiencies is crucial because they are treatable conditions that can present with cognitive decline mirroring neurodegenerative dementias.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient demonstrates insidious, progressive cognitive decline affecting instrumental activities of daily living without focal neurological deficits, highly suggestive of a major neurocognitive disorder (dementia).
Establishing the clinical syndrome dictates the subsequent diagnostic pathway.
2
Determine the standard guidelines for the initial evaluation of suspected dementia.
The initial evaluation must include screening for common, potentially reversible metabolic and systemic causes of cognitive impairment.
Before diagnosing irreversible neurodegenerative conditions like Alzheimer disease, treatable etiologies must be formally excluded.
3
Select the appropriate initial laboratory tests based on guidelines.
Routine laboratory screening requires concurrent testing of serum TSH and Vitamin B12 levels, alongside basic chemistries and a complete blood count.
Hypothyroidism and Vitamin B12 deficiency are classic, reversible causes of cognitive impairment that can mimic primary dementias.

Key Concept

The initial diagnostic evaluation of progressive cognitive impairment requires objective cognitive testing, structural neuroimaging, and specific laboratory screening (TSH and Vitamin B12) to rule out reversible causes.
Estimated Time:1m 30s
Question 4542Question →

A 5454-year-old man is evaluated on the inpatient medical ward 1212 hours after being admitted for increased abdominal girth, low-grade fever, and mild confusion. He has a history of decompensated cirrhosis due to chronic hepatitis C infection and alcohol use disorder. Temperature is 37.9∘C37.9^\circ\text{C} (100.2∘F100.2^\circ\text{F}), pulse is 98/min98/\text{min}, and blood pressure is 105/65 mmHg105/65 \text{ mmHg}. Physical examination reveals scleral icterus, spider angiomas, and tense ascites with shifting dullness. Asterixis is present.

Laboratory studies show:
Leukocyte count: 11,500/mm311,500/\text{mm}^3
Platelet count: 85,000/mm385,000/\text{mm}^3
Blood urea nitrogen: 42 mg/dL42 \text{ mg/dL}
Serum creatinine: 2.3 mg/dL2.3 \text{ mg/dL} (Baseline 33 months ago was 1.1 mg/dL1.1 \text{ mg/dL})
Total bilirubin: 4.5 mg/dL4.5 \text{ mg/dL}
Serum albumin: 2.4 g/dL2.4 \text{ g/dL}

Diagnostic paracentesis is performed, and ascitic fluid analysis reveals an absolute neutrophil count of 650/mm3650/\text{mm}^3 and total protein of 1.2 g/dL1.2 \text{ g/dL}. The patient is immediately started on intravenous cefotaxime and oral lactulose.

Which of the following is the most appropriate additional pharmacologic intervention at this time?

Show answer & explanation

Answer: Intravenous albumin

Answer

Intravenous albumin
The correct answer is intravenous albumin. This patient has spontaneous bacterial peritonitis (SBP), diagnosed by an ascitic fluid absolute neutrophil count ≥250/mm3\geq 250/\text{mm}^3. SBP is a common precipitant of hepatorenal syndrome (HRS), a form of acute kidney injury caused by severe splanchnic arterial vasodilation and subsequent renal vasoconstriction. To mitigate this risk, patients with SBP should receive intravenous albumin (1.5 g/kg1.5 \text{ g/kg} on day 1 and 1.0 g/kg1.0 \text{ g/kg} on day 3) if they meet any of the following high-risk criteria: serum creatinine >1.0 mg/dL> 1.0 \text{ mg/dL}, blood urea nitrogen >30 mg/dL> 30 \text{ mg/dL}, or total bilirubin >4.0 mg/dL> 4.0 \text{ mg/dL}. This patient meets all three criteria. Albumin acts as a plasma volume expander, improving effective circulating arterial volume and renal perfusion, which significantly reduces both the incidence of HRS and overall mortality.

Step-by-Step Solution

1
Diagnose the primary acute pathology based on ascitic fluid analysis.
The patient has spontaneous bacterial peritonitis (SBP), confirmed by an ascitic fluid absolute neutrophil count (ANC) ≥250/mm3\geq 250/\text{mm}^3.
Identifying SBP is the first step in directing targeted antimicrobial and adjunctive therapies.
2
Assess the patient's renal function and associated laboratory parameters.
The patient has acute kidney injury (creatinine elevated to 2.3 mg/dL2.3 \text{ mg/dL} from 1.1 mg/dL1.1 \text{ mg/dL}), elevated BUN (42 mg/dL42 \text{ mg/dL}), and elevated bilirubin (4.5 mg/dL4.5 \text{ mg/dL}).
SBP frequently triggers a systemic inflammatory response that worsens splanchnic vasodilation, leading to profound renal hypoperfusion and hepatorenal syndrome (HRS).
3
Select the appropriate adjunctive pharmacologic therapy to prevent renal failure.
Intravenous albumin is indicated.
Guidelines require the administration of intravenous albumin (1.5 g/kg1.5 \text{ g/kg} on day 1, and 1.0 g/kg1.0 \text{ g/kg} on day 3) for SBP patients who have a serum creatinine >1.0 mg/dL> 1.0 \text{ mg/dL}, BUN >30 mg/dL> 30 \text{ mg/dL}, or total bilirubin >4.0 mg/dL> 4.0 \text{ mg/dL} to expand intravascular volume, prevent HRS, and reduce mortality.

Key Concept

Patients with spontaneous bacterial peritonitis (SBP) who have concurrent renal impairment (creatinine >1.0 mg/dL> 1.0 \text{ mg/dL}, BUN >30 mg/dL> 30 \text{ mg/dL}) or severe liver disease (bilirubin >4.0 mg/dL> 4.0 \text{ mg/dL}) require adjunctive intravenous albumin on days 1 and 3 to prevent hepatorenal syndrome and reduce mortality.
Question 4543Question →

A 6868-year-old man is evaluated in the cardiology clinic for a follow-up of heart failure with reduced ejection fraction. His left ventricular ejection fraction is 32%32\%. He is currently treated with sacubitril-valsartan, carvedilol, and furosemide. He reports mild exertional dyspnea but denies orthopnea or peripheral edema. Current vital signs are blood pressure 118/75 mmHg118/75\text{ mmHg} and heart rate 64/min64\text{/min}.

Laboratory studies from today show:
ParameterResult
Serum sodium139 mEq/L139\text{ mEq/L}
Serum potassium4.1 mEq/L4.1\text{ mEq/L}
Serum creatinine1.1 mg/dL1.1\text{ mg/dL}
Blood urea nitrogen19 mg/dL19\text{ mg/dL}

The physician decides to initiate spironolactone to further optimize his heart failure regimen. The patient is counseled on the new medication. Which of the following laboratory parameters are strictly recommended to be monitored 11 to 22 weeks after initiating this specific therapy? (Select 2)

Select all that apply

Show answer & explanation

Answer: Serum potassium; Serum creatinine

Answer

The correct parameters to monitor are Serum potassium and Serum creatinine.
The correct parameters to monitor are Serum potassium and Serum creatinine. Spironolactone is a mineralocorticoid receptor antagonist (MRA) that blocks aldosterone, leading to decreased potassium excretion and potential alterations in renal hemodynamics. When combined with an angiotensin receptor-neprilysin inhibitor (ARNI) like sacubitril-valsartan, the risk of hyperkalemia and acute kidney injury is substantially elevated. Clinical guidelines strictly mandate rechecking serum potassium and renal function (creatinine) 11 to 22 weeks after initiation or dose titration of an MRA to prevent life-threatening arrhythmias and renal failure.

Step-by-Step Solution

1
Identify the new medication and its pharmacological class.
Spironolactone is a mineralocorticoid receptor antagonist (MRA).
Understanding the drug class is essential to predicting its physiological effects and adverse event profile.
2
Analyze the patient's concurrent medications for potential interactions.
The patient is taking sacubitril-valsartan, which contains an angiotensin II receptor blocker (ARB) that also inhibits the renin-angiotensin-aldosterone system (RAAS).
Concurrent use of multiple RAAS inhibitors multiplicatively increases the risk of specific adverse effects.
3
Determine the required monitoring based on the pharmacodynamic interaction.
The combination of an MRA and an ARB significantly increases the risk of severe hyperkalemia and acute kidney injury.
Clinical guidelines strictly mandate rechecking potassium and renal function 1 to 2 weeks after initiating an MRA to prevent life-threatening complications.

Key Concept

Patients initiated on mineralocorticoid receptor antagonists (e.g., spironolactone), especially those concurrently taking other RAAS inhibitors, require monitoring of serum potassium and renal function (creatinine) within 1 to 2 weeks to prevent severe hyperkalemia and acute kidney injury.
Estimated Time:1m 0s
Question 4544Question →

A 58-year-old man with a history of nonischemic cardiomyopathy is evaluated during a routine follow-up appointment. His left ventricular ejection fraction was 28%28\% on an echocardiogram performed 1 week ago. The patient reports stable but persistent exertional dyspnea (New York Heart Association class II). His current daily medications include maximally tolerated lisinopril, carvedilol, dapagliflozin, and spironolactone. His vital signs are temperature 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure 118/76 mmHg118/76\text{ mmHg}, and heart rate 68/min68\text{/min}. Physical examination reveals clear lungs and trace bilateral pedal edema. Laboratory studies show a serum potassium of 4.2 mEq/L4.2\text{ mEq/L} and creatinine of 1.1 mg/dL1.1\text{ mg/dL}. The physician plans to discontinue lisinopril and initiate sacubitril-valsartan to optimize guideline-directed medical therapy.

Which of the following are required components of the transition protocol and short-term monitoring plan for this patient? (Select 2)

Select all that apply

Show answer & explanation

Answer: Enforce a minimum 36-hour washout period after the final dose of lisinopril before starting sacubitril-valsartan; Evaluate serum potassium and creatinine levels 1 to 2 weeks after initiating the new therapy

Answer

The necessary steps are to enforce a 36-hour washout period after stopping the ACE inhibitor and to check serum potassium and creatinine levels 1 to 2 weeks after initiating the ARNI.
Transitioning a patient from an ACE inhibitor to an angiotensin receptor-neprilysin inhibitor (ARNI) requires specific safety protocols and monitoring. First, a strict 36-hour washout period is mandatory between the last dose of the ACE inhibitor and the first dose of the ARNI. Because both medications increase bradykinin levels, overlapping their administration significantly increases the risk of life-threatening angioedema. Second, like other renin-angiotensin-aldosterone system (RAAS) inhibitors, ARNIs can cause hyperkalemia and acute kidney injury due to changes in renal hemodynamics. Current guidelines mandate checking a basic metabolic panel to assess serum potassium and creatinine within 1 to 2 weeks after initiation or dose escalation.

Step-by-Step Solution

1
Identify the specific pharmacological transition occurring in the clinical vignette.
The patient is being switched from an ACE inhibitor (lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI; sacubitril-valsartan).
Different medication transitions carry unique interaction risks and protocol requirements.
2
Determine the safety protocols required for initiating an ARNI after an ACE inhibitor.
A strict 36-hour washout period is required between the last dose of lisinopril and the first dose of sacubitril-valsartan.
Both ACE inhibitors and neprilysin inhibitors increase bradykinin levels. Overlapping therapy poses a severe risk of life-threatening angioedema.
3
Identify the appropriate laboratory monitoring required after initiating an ARNI.
A basic metabolic panel must be drawn in 1 to 2 weeks to evaluate serum potassium and creatinine.
Like other RAAS inhibitors, ARNIs can cause hyperkalemia and acute kidney injury, particularly in patients taking concomitant mineralocorticoid receptor antagonists (spironolactone).
4
Evaluate the remaining options for clinical appropriateness.
Routine BNP monitoring is invalid, ICD reassessment at 4 weeks is premature, and stopping spironolactone inappropriately removes a mortality-benefit therapy.
To systematically eliminate common distractors related to heart failure management and biomarker interpretation.

Key Concept

Transitioning a patient from an ACE inhibitor to an ARNI requires a mandatory 36-hour washout period to prevent angioedema, followed by renal function and potassium monitoring in 1 to 2 weeks.
Estimated Time:1m 30s
Question 4545Question →

A 42-year-old woman is brought to the emergency department by emergency medical services after collapsing and exhibiting generalized tonic-clonic motor activity. Upon arrival, she remains unresponsive with continuous rhythmic jerking of her extremities. Her husband states the seizure began approximately 12 minutes prior to arrival and has not ceased at any point. She has no known medical history and takes no medications. Vital signs show a temperature of 37.8°C (100.0°F), blood pressure of 135/85 mmHg, pulse of 118/min, and respirations of 18/min. Point-of-care blood glucose is 105 mg/dL. Two large-bore intravenous lines are rapidly established.

Arrange the following pharmacologic interventions in the correct protocolized sequence for the escalation of therapy in this patient, from initial first-line stabilization to the management of super-refractory symptoms.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing escalating status epilepticus is: 1) Intravenous lorazepam bolus, 2) Intravenous fosphenytoin loading dose, 3) Continuous intravenous propofol infusion, 4) Continuous intravenous pentobarbital infusion.
The standard protocol for status epilepticus dictates a strict time-based escalation of pharmacologic therapy. Phase 1 (0-10 min) requires a rapid-acting benzodiazepine like IV lorazepam to acutely halt seizure activity. Phase 2 (10-30 min) requires loading a long-acting antiepileptic such as IV fosphenytoin to prevent recurrence. Phase 3 (30-60 min, refractory status epilepticus) requires continuous general anesthetics like IV propofol or midazolam alongside intubation. Finally, Phase 4 (super-refractory, >24 hours) utilizes a deep barbiturate coma with IV pentobarbital, reserved as a last resort due to severe hemodynamic toxicity.

Step-by-Step Solution

1
Administer a rapid-acting benzodiazepine.
GABAergic inhibition is rapidly enhanced to acutely terminate the ongoing seizure.
Intravenous lorazepam is the drug of choice for early status epilepticus (0-10 minutes) because it penetrates the blood-brain barrier quickly and has a longer duration of seizure suppression in the CNS compared to diazepam.
2
Administer a long-acting, non-benzodiazepine antiepileptic drug.
A sustained seizure threshold is established.
Because the antiepileptic effect of benzodiazepines is transient, an agent like fosphenytoin, levetiracetam, or valproic acid must be loaded during the established status epilepticus phase (10-30 minutes) to prevent recurrence or treat persistent activity.
3
Induce a continuous anesthetic coma.
Cerebral metabolic demand is suppressed, and refractory seizure activity is aborted.
Status epilepticus lasting longer than 30 minutes is considered refractory and carries a high risk of permanent neuronal injury. After securing the airway, continuous infusions of propofol or midazolam are titrated to burst suppression on an electroencephalogram (EEG).
4
Escalate to super-refractory barbiturate therapy.
Profound suppression of all electrographic brain activity is achieved.
If seizures continue or recur after 24 hours of anesthetic infusion, the condition is super-refractory. Pentobarbital is used as a definitive, last-line measure due to its extreme side effect profile, which includes vasoplegia requiring vasopressors.

Key Concept

The stepwise pharmacologic escalation protocol for status epilepticus (from initial benzodiazepines to super-refractory barbiturate coma).
Question 4546Question →

A 4242-year-old premenopausal woman presents to the oncology clinic for a scheduled evaluation prior to her next infusion. She is currently undergoing treatment for early-stage, HER2-amplified, estrogen receptor-negative breast cancer. She successfully completed a course of adjuvant paclitaxel and is currently receiving maintenance intravenous trastuzumab every 33 weeks.

During the clinical interview, the patient reports feeling well and denies shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, or peripheral swelling. She exercises moderately for 4545 minutes most days of the week without limitation. Vital signs include a blood pressure of 118/74118/74 mmHg and a heart rate of 7272/min. Physical examination reveals clear lungs bilaterally, no jugular venous distention, and a regular heart rate with no S3 gallop.

As part of her routine surveillance, serial echocardiography has been performed with the following results:

TimepointLeft Ventricular Ejection Fraction (LVEF)
Pre-treatment (Baseline)66%66\%
Week 121262%62\%
Week 2424 (Current)48%48\%

Based on the patient's surveillance data, which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Withhold trastuzumab and repeat echocardiography in 44 weeks

Answer

The most appropriate next step is to withhold trastuzumab and repeat echocardiography in 44 weeks.
The correct answer identifies the guideline-concordant management for asymptomatic trastuzumab-induced left ventricular dysfunction. Trastuzumab causes Type II cardiotoxicity, which involves loss of myocardial contractility without the irreversible myocyte destruction seen with anthracyclines. Because this toxicity is frequently reversible, standard oncology protocols dictate that for an absolute LVEF decline of 16%16\% or greater, or a decline to below 50%50\%, the medication must be temporarily held. An echocardiogram should then be repeated in 44 weeks. If the LVEF recovers to acceptable parameters, the medication can safely be resumed in the majority of cases.

Step-by-Step Solution

1
Identify the patient's current clinical status and medication.
The patient is asymptomatic but is receiving trastuzumab, an agent specifically known to cause Type II (typically reversible) cardiotoxicity.
Establishing the patient's symptom status and specific pharmacology is required to select the correct toxicity monitoring algorithm.
2
Analyze the longitudinal surveillance data against baseline measurements.
The patient's LVEF has dropped from a baseline of 66%66\% to a current value of 48%48\%. This is an absolute decrease of 18%18\% and falls below the standard institutional lower limit of normal (50%50\%).
Trastuzumab guidelines dictate management based on exact percentage drops from baseline, not just the absolute current value.
3
Apply standard oncologic monitoring guidelines for HER2-targeted therapy.
For an asymptomatic patient with an absolute LVEF decrease of ≥16%\ge 16\% from baseline, or a decrease of 10%−15%10\%-15\% to a value below institutional limits of normal, trastuzumab must be withheld.
Continuing the medication when these thresholds are crossed significantly increases the risk of progression to symptomatic heart failure.
4
Determine the mandatory follow-up sequencing.
Echocardiography should be repeated in 44 weeks to assess for reversibility before making any decision regarding permanent discontinuation.
Type II cardiotoxicity often resolves upon holding the drug, allowing for safe resumption of life-saving cancer therapy if LVEF recovers.

Key Concept

Trastuzumab-induced cardiotoxicity presents as asymptomatic, reversible left ventricular systolic dysfunction (Type II cardiotoxicity), necessitating strict serial monitoring and algorithmic withholding of the drug for absolute LVEF declines ≥16%\ge 16\%, followed by reassessment in 44 weeks.
Estimated Time:1m 30s
Question 4547Question →

A 66-year-old woman comes to the clinic for a routine health maintenance examination. She feels well and has no acute complaints. Her medical history is notable for mild primary hypertension, which is well controlled on lisinopril. She does not use tobacco, alcohol, or illicit substances. She has been in a mutually monogamous relationship with her husband for 40 years.

Review of her medical records reveals the following:
- Screening mammography at age 65 was normal.
- Screening colonoscopy at age 60 showed no polyps.
- Dual-energy x-ray absorptiometry at age 65 showed normal bone mineral density.
- Cervical cancer screening via cytology and high-risk human papillomavirus (hrHPV) co-testing was performed at ages 59 and 64; both results were negative.
- She received the 20-valent pneumococcal conjugate vaccine (PCV20) at age 65.
- She received a two-dose series of the recombinant zoster vaccine at age 65.
- She received a Tdap booster at age 61.
- Medical records indicate she has never been screened for hepatitis C.

Vital signs and physical examination findings are within normal limits. Which of the following is the most appropriate next step in preventive care for this patient?

Show answer & explanation

Answer: Hepatitis C virus antibody testing

Answer

Hepatitis C virus antibody testing
The correct answer is Hepatitis C virus antibody testing. The USPSTF recommends a one-time screening for hepatitis C virus (HCV) infection in all asymptomatic adults aged 18 to 79 years without known liver disease. Because this patient has no documented prior screening and is within the recommended age range, she should undergo HCV antibody testing now.

Step-by-Step Solution

1
Evaluate the patient's age and demographic risk factors.
The patient is a 66-year-old female with no history of tobacco use and no high-risk sexual or drug use behaviors.
Age and specific risk factors dictate which USPSTF and ACIP screening guidelines apply.
2
Assess current adherence to age-appropriate screening guidelines.
The patient is up to date on breast cancer, colorectal cancer, and osteoporosis screenings. She meets criteria to discontinue cervical cancer screening and has aged out of routine HIV screening.
Eliminating up-to-date and age-inappropriate screenings narrows down the remaining indicated tests.
3
Identify any omitted routine screening tests.
The patient has never received a one-time screening for the hepatitis C virus.
USPSTF guidelines mandate universal one-time HCV screening for all adults aged 18 to 79 years.

Key Concept

Application of upper age limits for routine preventive screenings (USPSTF guidelines)
Estimated Time:1m 0s
Question 4548Question →

A 6464-year-old man with a history of type 2 diabetes mellitus, hypertension, and hyperlipidemia is evaluated in the outpatient clinic for a routine follow-up. He feels well and reports no new symptoms, including no changes in urine output or peripheral edema. His current medications include metformin 1000 mg1000\text{ mg} twice daily, empagliflozin 10 mg10\text{ mg} daily, lisinopril 20 mg20\text{ mg} daily, and atorvastatin 40 mg40\text{ mg} daily. Vital signs show a blood pressure of 130/80 mmHg130/80\text{ mmHg} and a heart rate of 72/min72/\text{min}. Physical examination is unremarkable.

Laboratory results from the current and previous visits are shown below:

Parameter12 Months Ago6 Months AgoCurrent Visit
Hemoglobin A1c8.2%8.2\%7.5%7.5\%7.3%7.3\%
Serum creatinine1.6 mg/dL1.6\text{ mg/dL}1.8 mg/dL1.8\text{ mg/dL}2.5 mg/dL2.5\text{ mg/dL}
Estimated GFR45 mL/min/1.73 m245\text{ mL/min/1.73 m}^240 mL/min/1.73 m240\text{ mL/min/1.73 m}^226 mL/min/1.73 m226\text{ mL/min/1.73 m}^2
Serum potassium4.3 mEq/L4.3\text{ mEq/L}4.6 mEq/L4.6\text{ mEq/L}4.9 mEq/L4.9\text{ mEq/L}
Urine albumin-to-creatinine ratio380 mg/g380\text{ mg/g}340 mg/g340\text{ mg/g}290 mg/g290\text{ mg/g}

Based on these findings, which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Discontinue metformin

Answer

The most appropriate next step is to discontinue metformin.
The correct action is to discontinue metformin. Metformin is primarily renally excreted, and its accumulation in severe chronic kidney disease significantly increases the risk of metformin-associated lactic acidosis. Current prescribing guidelines mandate that metformin must be permanently discontinued when a patient's estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m230\text{ mL/min/1.73 m}^2. Because this patient's eGFR has dropped to 26 mL/min/1.73 m226\text{ mL/min/1.73 m}^2 (CKD stage 4), removing this medication is the most urgent and appropriate next step.

Step-by-Step Solution

1
Analyze the patient's laboratory trends over the past year.
The patient's estimated glomerular filtration rate (eGFR) has progressively declined from 4545 to 26 mL/min/1.73 m226\text{ mL/min/1.73 m}^2, placing him in chronic kidney disease (CKD) stage 4.
Tracking longitudinal kidney function is essential to adjust renally cleared medications and prevent toxicity.
2
Evaluate the safety profile of the patient's current medications at an eGFR of 26 mL/min/1.73 m226\text{ mL/min/1.73 m}^2.
Metformin requires discontinuation, while empagliflozin and lisinopril can safely be continued to provide ongoing nephroprotection.
Various medications have strict eGFR cutoffs for dosing or absolute contraindications to avoid severe adverse events.
3
Identify the critical required intervention.
Metformin must be stopped immediately.
Metformin accumulation in severe CKD significantly increases the risk of life-threatening lactic acidosis.

Key Concept

Metformin must be permanently discontinued when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m230\text{ mL/min/1.73 m}^2 to prevent lactic acidosis.
Estimated Time:1m 30s
Question 4549Question →

During an evaluation for treatment-resistant hypertension, diaphoresis, and episodic tachycardia, a patient is found to have significantly elevated 2424-hour urine fractionated metanephrines. Subsequent cross-sectional abdominal imaging confirms a unilateral 4.54.5-cm adrenal mass, establishing the diagnosis of a pheochromocytoma. A multidisciplinary team plans a definitive surgical intervention.

Arrange the following perioperative management steps in the mandatory chronological order required to safely optimize the patient and prevent catastrophic hemodynamic instability.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for the surgical preparation and management of a pheochromocytoma is to first initiate alpha-adrenergic blockade, followed by beta-adrenergic blockade, then administer volume expansion, and finally perform the surgical resection.
The correct chronological sequence safely prepares the patient for the physiological stress of a pheochromocytoma resection. Alpha-blockade (typically phenoxybenzamine) must be started 10-14 days prior to surgery to control blood pressure and expand the vascular bed. Beta-blockade is added subsequently (2-3 days later) to manage resulting tachycardia. Because the patient is chronically volume depleted from prolonged vasoconstriction, generous sodium loading and preoperative intravenous crystalloids are administered next. Once hemodynamically optimized, the patient can safely undergo definitive surgical adrenalectomy.

Step-by-Step Solution

1
Identify the primary physiological derangement caused by the tumor.
Recognize that pheochromocytomas continuously secrete catecholamines, resulting in severe alpha-receptor-mediated vasoconstriction, chronic hypertension, and secondary intravascular volume depletion.
Understanding the baseline hemodynamics dictates the necessary pharmacological sequence to prevent intraoperative mortality.
2
Determine the first line of medical optimization.
Identify that an alpha-adrenergic antagonist must be administered first to reverse the systemic vasoconstriction.
Lowering peripheral vascular resistance safely reduces blood pressure and begins the process of accommodating a normal intravascular volume.
3
Sequence the management of associated tachycardia.
Determine that a beta-adrenergic antagonist is added only after adequate alpha-blockade has been established.
Administering a beta-blocker first would eliminate beta-2 mediated vasodilation, leaving alpha-1 vasoconstriction unopposed and precipitating a potentially fatal hypertensive crisis.
4
Identify the final required stabilization steps before definitively removing the tumor.
Recognize that intravenous volume expansion must be performed immediately preoperatively, followed by the definitive adrenalectomy.
Tumor removal abruptly halts catecholamine release; if the patient's vascular bed is dilated but underfilled, they will experience profound hypotensive shock upon resection.

Key Concept

The perioperative surgical pathway for pheochromocytoma mandates strict sequential administration of alpha-blockade followed by beta-blockade and subsequent intravascular volume expansion prior to definitive tumor resection.
Question 4550Question →

A 72-year-old man comes to the clinic to establish care. He recently moved to the area to live closer to his daughter and has not seen a physician in over 10 years. His past medical history includes hypertension, which is well controlled on amlodipine. He smoked one pack of cigarettes daily from age 20 to 55 but has not smoked since. He drinks alcohol occasionally. His blood pressure is 128/82 mmHg, pulse is 72/min, and BMI is 24 kg/m². Physical examination is unremarkable. He has not undergone any cancer screening or preventive testing in the past decade. Based on current guidelines, which of the following preventive interventions are indicated for this patient today? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Abdominal ultrasonography; Screening for colorectal cancer

Answer

The indicated preventive interventions for this patient are abdominal ultrasonography and screening for colorectal cancer.
Based on USPSTF guidelines, this 72-year-old man requires a one-time screening for an abdominal aortic aneurysm (AAA) via abdominal ultrasonography because he is a male aged 65 to 75 who has smoked at least 100 cigarettes in his lifetime. He also requires screening for colorectal cancer because he is between the ages of 45 and 75 and is overdue (having not seen a physician in over 10 years).

Step-by-Step Solution

1
Evaluate the patient's demographics and vital signs against screening guidelines.
The patient is a 72-year-old male with a normal BMI of 24 kg/m².
Age and BMI dictate eligibility for several screenings (e.g., colorectal cancer, diabetes, prostate cancer).
2
Evaluate the patient's smoking history.
He has a 35 pack-year smoking history but quit 17 years ago.
Smoking history is required to determine the need for lung cancer and abdominal aortic aneurysm (AAA) screening.
3
Apply the USPSTF criteria for each potential intervention to identify indicated tests.
He requires AAA screening (men 65-75, ever smoker) and colorectal cancer screening (all adults 45-75). He does not require lung cancer screening (quit >15 years ago), PSA testing (age >70), or diabetes screening (age >70, normal BMI).
Evidence-based guidelines ensure that the benefits of screening outweigh the potential harms.

Key Concept

Application of age- and risk-based USPSTF preventive screening guidelines for older adults, particularly emphasizing the 'stop screening' criteria for lung cancer and prostate cancer.
Estimated Time:1m 30s
Question 4551Question →

An 82-year-old man who resides in a skilled nursing facility is evaluated in the emergency department for a two-day history of progressively worsening abdominal pain, an inability to pass flatus, and recurrent bilious vomiting. He has a history of Parkinson disease, chronic constipation, and hypertension. His daily medications include carbidopa-levodopa, lisinopril, and polyethylene glycol. His temperature is 38.6°C (101.5°F), blood pressure is 88/56 mm Hg, pulse is 122/min, and respirations are 24/min. On physical examination, the patient appears lethargic and is in significant distress. The abdomen is grossly distended and tympanitic. There is marked rigidity, involuntary guarding, and rebound tenderness across all quadrants. Bowel sounds are absent. A digital rectal examination reveals an empty rectal vault. Laboratory studies show a leukocyte count of 19,200/mm³ and a serum lactate level of 4.8 mmol/L. An anteroposterior abdominal radiograph reveals a massively dilated large bowel loop resembling a "coffee bean" extending from the pelvis toward the right upper quadrant. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Emergent exploratory laparotomy

Answer

Emergent exploratory laparotomy
The most appropriate next step in management is an emergent exploratory laparotomy. This patient's presentation of massive abdominal distention, obstipation, and an abdominal radiograph showing a "coffee bean" sign is highly characteristic of a sigmoid volvulus. While an uncomplicated sigmoid volvulus is typically managed with flexible sigmoidoscopy to decompress and detorse the bowel, this patient is exhibiting clear signs of a complicated volvulus, specifically bowel ischemia or gangrene. These signs include fever, hemodynamic instability (hypotension, tachycardia), severe lactic acidosis, and frank peritonitis (rigidity, guarding, and rebound tenderness). When peritonitis or bowel compromise is present, endoscopic interventions are strictly contraindicated due to the high risk of exacerbating a perforation. The patient requires immediate fluid resuscitation and an emergent laparotomy to resect the necrotic segment of the colon (often via a Hartmann procedure).

Step-by-Step Solution

1
Identify the primary diagnosis based on clinical and radiographic findings.
Sigmoid volvulus.
The patient is an elderly individual with chronic constipation presenting with severe abdominal distention and an abdominal radiograph showing the classic "coffee bean" sign.
2
Assess for complications that alter the management pathway.
The patient has peritonitis and likely bowel ischemia.
Clinical examination reveals a rigid abdomen with rebound tenderness, accompanied by fever, hemodynamic instability (tachycardia, hypotension), leukocytosis, and lactic acidosis.
3
Determine the appropriate procedural intervention.
Emergent exploratory laparotomy.
In the setting of a complicated volvulus (gangrene, peritonitis, or perforation), endoscopic detorsion is contraindicated; immediate surgical source control with likely bowel resection is required.

Key Concept

Surgical management of complicated sigmoid volvulus
Question 4552Question →

A spouse brings her 4545-year-old husband to the emergency department due to profound confusion and worsening hand tremors over the past 4848 hours. The patient carries a diagnosis of bipolar disorder and has been stable on medication for years. Two weeks ago, he was prescribed lisinopril for newly diagnosed hypertension. On physical examination, his blood pressure is 112/72 mm Hg112/72 \text{ mm Hg} and heart rate is 88 /min88 \text{ /min}. He is somnolent, exhibits severe truncal ataxia, and demonstrates hyperreflexia in all extremities. Electrocardiography reveals a normal sinus rhythm. Given the high clinical suspicion for drug toxicity, arrange the following steps in the optimal chronological sequence for the monitoring, evaluation, and therapeutic escalation in this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with immediate cessation of lithium and lisinopril alongside diagnostic baseline testing, followed by aggressive isotonic saline hydration. Frequent monitoring of serum levels then dictates the necessity of escalating to hemodialysis, after which the patient must be monitored for rebound toxicity.
The correct chronological management of lithium toxicity follows a strict paradigm of source control, physiological enhancement of clearance, close monitoring to evaluate the response, escalation to mechanical clearance if conservative measures fail, and post-intervention surveillance. Stopping the offending drugs (lithium and the precipitating ACE inhibitor) establishes safety. Aggressive isotonic saline then exploits renal physiology to flush the drug. Monitoring every 22 to 44 hours is necessary to track the clearance rate. If the patient's severe neurotoxicity persists or levels remain dangerously high despite fluids, hemodialysis is indicated. Finally, because lithium equilibrates slowly between intracellular and extracellular compartments, post-dialysis monitoring is mandatory to catch rebound toxicity.

Step-by-Step Solution

1
Recognize the precipitation of acute-on-chronic lithium toxicity by an ACE inhibitor and remove the triggers.
Discontinuation of lithium and lisinopril, and acquisition of baseline metabolic and drug levels.
ACE inhibitors reduce the glomerular filtration rate and promote the proximal tubular reabsorption of lithium, leading to systemic toxicity. Removing the physiological trigger is paramount before any other intervention.
2
Initiate first-line conservative therapy.
Administration of aggressive intravenous 0.9%0.9\% sodium chloride.
Sodium and volume loading inhibit the proximal tubular reabsorption of lithium, which maximizes renal clearance as long as the patient's renal function and cardiac output can tolerate the fluid load.
3
Assess the clinical and biochemical response to initial therapy.
Serial monitoring of lithium levels and neurological exams every 22 to 44 hours.
This monitoring determines the efficacy of fluid therapy and identifies patients who are failing conservative management and crossing the threshold for dialysis.
4
Escalate therapy for severe or refractory cases.
Intermittent hemodialysis.
Hemodialysis is the definitive step-up therapy required if levels remain critically high (e.g., >4.0 mEq/L>4.0 \text{ mEq/L}) or if severe neurotoxicity (such as lethargy and ataxia) fails to improve with fluids.
5
Perform post-escalation safety monitoring.
Checking for rebound serum lithium levels post-dialysis.
Intracellular lithium redistributes into the extracellular space once dialysis clears the blood, which can cause a secondary spike in serum levels and recurrent symptoms.

Key Concept

The stepwise management of severe lithium toxicity requires discontinuation of precipitating agents, initial enhancement of physiological clearance via aggressive isotonic hydration, serial monitoring of treatment response, escalation to hemodialysis for refractory/severe cases, and surveillance for post-dialysis rebound.
Estimated Time:2m 0s
Question 4553Question →

A 58-year-old woman is brought to the emergency department by her family after vomiting a large amount of bright red blood. The patient has a history of decompensated alcoholic cirrhosis but has not seen a physician in over a year. On arrival, she appears pale, lethargic, and diaphoretic. Temperature is 36.5°C (97.7°F), blood pressure is 82/50 mmHg, pulse is 124/min, and respiratory rate is 22/min. Oxygen saturation is 96% on room air. Physical examination reveals scleral icterus, multiple spider angiomas on the chest, and a distended abdomen with a positive fluid wave.

Laboratory studies show:
TestResult
Hemoglobin7.4 g/dL
Platelet count88,000/mm³
Prothrombin time18 seconds
INR1.9
Blood urea nitrogen42 mg/dL
Creatinine1.3 mg/dL

Two large-bore peripheral intravenous lines are placed, and rapid fluid resuscitation with crystalloid is initiated. A massive transfusion protocol is on standby. The gastroenterology team is consulted for an emergent upper endoscopy.

Which of the following pharmacologic interventions should be administered immediately in this patient? (Select all that apply.)

Select all that apply

Show answer & explanation

Answer: Intravenous octreotide; Intravenous ceftriaxone; Intravenous pantoprazole

Answer

The correct interventions are intravenous octreotide, intravenous ceftriaxone, and intravenous pantoprazole.
In a patient presenting with an acute upper gastrointestinal hemorrhage and signs of decompensated cirrhosis, the immediate goals are hemodynamic resuscitation and prevention of complications. Intravenous octreotide is required to induce splanchnic vasoconstriction, which directly lowers portal venous pressure and reduces bleeding. Intravenous ceftriaxone is essential because bacterial infections (such as spontaneous bacterial peritonitis) are a major cause of mortality and rebleeding in cirrhotic patients with GI bleeds. Intravenous pantoprazole should be administered empirically because up to 20% of upper GI bleeds in patients with cirrhosis are caused by peptic ulcer disease rather than varices.

Step-by-Step Solution

1
Diagnose the clinical condition.
The patient is in hypovolemic shock secondary to acute upper gastrointestinal bleeding, highly suspicious for variceal hemorrhage given her stigmata of decompensated cirrhosis.
Bright red hematemesis, hypotension, tachycardia, and a history of alcoholic cirrhosis with ascites point to variceal bleeding as the primary differential.
2
Determine the immediate pharmacologic priorities prior to endoscopy.
Identify the triad of empiric medications required: splanchnic vasoconstrictors, prophylactic antibiotics, and acid suppression.
Endoscopy is the definitive management, but pharmacologic stabilization reduces portal pressure, prevents life-threatening infections, and protects against possible peptic ulcer bleeding.
3
Identify contraindicated interventions.
Exclude propranolol and fresh frozen plasma.
Propranolol blunts the physiologic response to shock. Fresh frozen plasma unnecessarily expands intravascular volume, paradoxically worsening portal hypertension and bleeding, without effectively correcting the complex coagulopathy of cirrhosis.

Key Concept

The initial pharmacologic management of suspected acute variceal hemorrhage in a patient with cirrhosis requires the concurrent administration of a splanchnic vasoconstrictor (e.g., octreotide), prophylactic antibiotics (e.g., ceftriaxone), and a proton pump inhibitor, while avoiding non-selective beta-blockers and routine fresh frozen plasma.
Question 4554Question →

A 58-year-old woman is evaluated on hospital day 22 for discharge planning. She was initially admitted for severe acute necrotizing pancreatitis complicated by acute respiratory distress syndrome, requiring prolonged intubation. She eventually underwent a tracheostomy placement for failure to wean. Currently, she is hemodynamically stable and no longer requires vasopressor support. She is tolerating a tracheostomy collar for 6 hours during the day but requires continuous mechanical ventilation overnight. Her abdominal surgical wounds are open and require twice-daily complex packing with negative pressure wound therapy. She is alert, follows simple commands, and participates in physical therapy for approximately 30 minutes daily before experiencing severe fatigue. She continues to receive intravenous antibiotics for a multidrug-resistant intra-abdominal infection, which requires daily physician monitoring of her renal function and drug levels. Which of the following is the most appropriate disposition for this patient?

Show answer & explanation

Answer: Transfer to a long-term acute care hospital

Answer

Transfer to a long-term acute care hospital
The correct disposition is a long-term acute care hospital (LTACH). This patient has survived a critical illness and is hemodynamically stable, meaning she no longer requires the intensive 1:1 or 1:2 nursing ratios of an ICU. However, she has substantial ongoing medical needs, including active mechanical ventilator weaning, complex twice-daily surgical wound packing, and intravenous antibiotics requiring daily physician monitoring of drug levels and renal function. LTACHs are specifically designed for patients with extended medical and rehabilitative needs who require daily, on-site physician intervention and high-acuity nursing care but cannot tolerate the intensive therapy required of an inpatient rehabilitation facility.

Step-by-Step Solution

1
Assess the patient's current medical stability and active medical needs.
The patient is hemodynamically stable but requires prolonged ventilator weaning, complex wound care, and daily physician management for IV antibiotics.
Determining the acuity of ongoing medical care establishes the baseline capability required of the receiving facility.
2
Assess the patient's functional capacity and rehabilitation potential.
The patient is alert and participating in therapy but has severe deconditioning, limiting her tolerance to 30 minutes of physical therapy daily.
Functional tolerance dictates whether the patient qualifies for intensive inpatient rehabilitation versus slower-paced care settings.
3
Match the combined medical acuity and functional tolerance to the appropriate care setting.
LTACH criteria are met (complex medical needs, daily physician oversight, inability to tolerate 3 hours of therapy). IRF, SNF, and home discharge are ruled out based on therapy tolerance and medical complexity.
Safe transitions of care require precise alignment between patient needs and facility capabilities.

Key Concept

Disposition to a Long-Term Acute Care Hospital (LTACH) is indicated for patients who are hemodynamically stable but have complex medical conditions requiring daily physician monitoring, specialized nursing, or respiratory therapy (such as prolonged mechanical ventilation weaning), and who cannot tolerate intensive rehabilitation.
Estimated Time:1m 30s
Question 4555Question →

A 45-year-old woman is evaluated in the gastroenterology clinic for a 9-month history of severe, burning epigastric pain and chronic watery diarrhea. Her symptoms have been refractory to high-dose omeprazole therapy. An esophagogastroduodenoscopy performed three weeks ago revealed thickened gastric folds and multiple ulcerations in the duodenal bulb and the distal duodenum. The patient was instructed to discontinue her proton pump inhibitor for one week prior to today's visit, utilizing only calcium carbonate antacids for symptom relief. Vital signs are within normal limits. Physical examination reveals mild epigastric tenderness. Laboratory testing shows a fasting serum gastrin level of 640 pg/mL (Normal: < 100 pg/mL). A concurrent gastric fluid analysis demonstrates a basal gastric pH of 1.5. Which of the following is the most appropriate next step in the diagnostic workup?

Show answer & explanation

Answer: Secretin stimulation test

Answer

The most appropriate next step is a secretin stimulation test to biochemically confirm the diagnosis of Zollinger-Ellison syndrome.
This patient's presentation of refractory peptic ulcer disease, distal duodenal ulcers, and diarrhea is highly suspicious for Zollinger-Ellison syndrome (ZES). The initial workup for ZES involves measuring fasting serum gastrin (FSG) off proton pump inhibitor therapy and assessing gastric pH. A gastric pH < 2.0 confirms that hypergastrinemia is not secondary to achlorhydria. If the FSG is > 1,000 pg/mL, the diagnosis of ZES is definitively confirmed. However, if the FSG is elevated but < 1,000 pg/mL (as seen in this patient with 640 pg/mL), the value is considered equivocal. The correct next step is provocative testing with a secretin stimulation test. Secretin normally inhibits gastrin release from normal gastric G cells but paradoxically stimulates gastrin release from gastrinoma cells. An increase in serum gastrin of > 120 pg/mL above basal levels following secretin administration confirms ZES.

Step-by-Step Solution

1
Analyze the clinical presentation and endoscopic findings.
The patient has refractory peptic ulcer disease, distal duodenal ulcers, thickened gastric folds, and chronic diarrhea.
These findings are highly suspicious for Zollinger-Ellison syndrome (gastrinoma), prompting evaluation of gastrin and acid levels.
2
Interpret the laboratory findings.
The fasting serum gastrin is elevated (640 pg/mL) and gastric pH is acidic (1.5).
A gastric pH < 2.0 excludes achlorhydria as a cause of hypergastrinemia. However, the gastrin level is in the equivocal range (100 to 1,000 pg/mL).
3
Determine the appropriate sequencing to confirm the diagnosis.
A secretin stimulation test is indicated.
Because the gastrin level is not definitively diagnostic (> 1,000 pg/mL), provocative testing with secretin is required before proceeding to tumor localization imaging.

Key Concept

In the workup of Zollinger-Ellison syndrome, an equivocal fasting serum gastrin level (100 to 1,000 pg/mL) in the setting of gastric pH < 2.0 requires provocative biochemical testing with a secretin stimulation test before obtaining localization imaging.
Question 4556Question →

A 34-year-old man is brought to the emergency department after a high-speed motor vehicle collision. He is pale, diaphoretic, and minimally responsive. Vital signs show a temperature of 36.2°C (97.2°F), blood pressure of 72/40 mm Hg, heart rate of 135/min, and respiratory rate of 24/min. The airway is patent, and breath sounds are equal bilaterally. A focused assessment with sonography for trauma (FAST) examination is negative for intraperitoneal fluid. Pelvic examination reveals significant instability to gentle anteroposterior compression. Intravenous access is established, and a massive transfusion protocol is initiated. Which of the following are the most appropriate immediate procedural and surgical interventions for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Application of a noninvasive pelvic circumferential compression device; Pelvic angiography with targeted arterial embolization

Answer

The correct procedural interventions are the application of a noninvasive pelvic circumferential compression device and pelvic angiography with targeted arterial embolization.
The patient is in hemorrhagic shock due to an unstable pelvic fracture. In the setting of a negative FAST examination, the life-threatening bleeding is located in the retroperitoneal space, originating from either the presacral venous plexus or pelvic arterial branches. The first critical procedural step is the application of a pelvic circumferential compression device, which reduces the pelvic volume, aligns the fractured bone ends, and promotes tamponade of venous bleeding. Because the patient remains hemodynamically unstable, he requires definitive management of potential arterial hemorrhage. Pelvic angiography with targeted arterial embolization (or preperitoneal pelvic packing) is the most appropriate concurrent or immediate subsequent step for achieving definitive arterial hemostasis.

Step-by-Step Solution

1
Identify the primary physiologic derangement.
The patient is in severe hemorrhagic shock (hypotension, tachycardia) following blunt trauma.
Recognizing the severity of shock guides the urgency of interventions.
2
Determine the source of bleeding based on physical exam and adjuncts.
The FAST exam is negative (no intraperitoneal bleeding), but the pelvis is mechanically unstable.
This localizes the life-threatening hemorrhage to the retroperitoneal space associated with the pelvic fracture.
3
Select the appropriate immediate stabilizing procedures.
Application of a pelvic binder and transfer for pelvic angiography are chosen.
A binder tamponades venous bleeding by reducing pelvic volume, while angiography identifies and embolizes arterial bleeders. Exploratory laparotomy must be avoided.

Key Concept

Management of hemodynamically unstable pelvic fractures involves immediate mechanical stabilization with a pelvic binder to control venous bleeding, followed by pelvic angiography (or preperitoneal packing) for arterial hemorrhage control, while avoiding laparotomy unless intraperitoneal bleeding is confirmed.
Question 4557Question →

An outpatient nephrology consultation is requested for a male patient who received a deceased-donor renal allograft four months prior. The patient reports a five-day history of persistent headaches, insomnia, and bilateral hand tremors that interfere with his ability to eat. He has also noticed a decline in his daily urine output. His maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and low-dose prednisone. Thirteen days ago, he was evaluated by an infectious disease specialist for invasive pulmonary aspergillosis, for which oral voriconazole therapy was initiated.

Vital signs today demonstrate a blood pressure of 168/98 mmHg, heart rate of 88/min, and temperature of 37.2°C (99.0°F). Physical examination reveals a fine, bilateral resting tremor in the upper extremities but is otherwise unremarkable.

Laboratory analysis shows:
TestResultReference Range
Blood urea nitrogen34 mg/dL8-20 mg/dL
Serum creatinine2.2 mg/dL0.7-1.3 mg/dL
Baseline creatinine (1 month ago)1.2 mg/dL0.7-1.3 mg/dL

Urinalysis is unremarkable with no proteinuria or cellular casts.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Check a serum tacrolimus trough concentration and decrease the dosage

Answer

Check a serum tacrolimus trough concentration and decrease the dosage
The correct approach addresses calcineurin inhibitor (CNI) toxicity. Tacrolimus is a CNI metabolized by the hepatic and intestinal cytochrome P450 3A4 (CYP3A4) system. Voriconazole is a potent inhibitor of CYP3A4. Co-administration significantly decreases tacrolimus clearance, leading to supratherapeutic levels. CNI toxicity typically presents with acute kidney injury (due to afferent arteriolar vasoconstriction), new-onset or worsening hypertension, and neurotoxicity (ranging from fine tremors and headaches to seizures). The most appropriate next step is to check a serum tacrolimus trough concentration and reduce the dosage to prevent further toxicity.

Step-by-Step Solution

1
Identify the patient's clinical syndrome.
The patient presents with acute kidney injury, new-onset hypertension, and neurotoxicity (tremors, headaches, insomnia).
Characterizing the constellation of symptoms narrows the differential diagnosis in a post-transplant patient.
2
Analyze the patient's medication history for potential adverse effects or interactions.
The patient recently started voriconazole while on a maintenance regimen of tacrolimus.
Drug-drug interactions are a primary cause of morbidity in transplant patients on complex pharmacological regimens.
3
Determine the mechanism of the interaction and its clinical consequences.
Voriconazole strongly inhibits CYP3A4, the enzyme responsible for metabolizing tacrolimus, leading to supratherapeutic tacrolimus levels and subsequent calcineurin inhibitor toxicity.
Understanding the pharmacokinetic mechanism allows for the correct intervention.
4
Select the most appropriate management step.
Checking a tacrolimus trough level and preemptively reducing the dose directly addresses the root cause of the patient's symptoms.
Drug level monitoring and dose adjustment is the standard of care for suspected calcineurin inhibitor toxicity.

Key Concept

Voriconazole strongly inhibits CYP3A4, reducing the metabolism of calcineurin inhibitors (like tacrolimus and cyclosporine). This leads to supratherapeutic levels and toxicity, manifesting as nephrotoxicity, neurotoxicity, and hypertension, requiring urgent therapeutic drug monitoring and dose reduction.

Alternative Method

In clinical practice, when starting a potent CYP3A4 inhibitor in a patient on tacrolimus, the tacrolimus dose is often empirically reduced by 30-50% simultaneously with the initiation of the new drug, followed by close therapeutic drug monitoring.
Estimated Time:1m 30s
Question 4558Question →

A 68-year-old woman is evaluated in the outpatient clinic for an annual preventive care visit. Her medical history includes primary hypertension, diet-controlled type 2 diabetes mellitus, and osteoarthritis of the right knee. Her current medications are amlodipine and as-needed ibuprofen. The patient is a lifetime nonsmoker and occasionally drinks wine with dinner.

Review of her preventive screening records shows a normal screening colonoscopy at age 65 and a normal bilateral mammogram 3 months ago. Bone densitometry performed at age 65 revealed a T-score of -1.1 at the lumbar spine. Recent laboratory studies show a hemoglobin A1c of 6.2% and a well-controlled lipid profile. Her vaccination history indicates she received the annual influenza vaccine recently, a Tdap booster 4 years ago, and completed the two-dose recombinant zoster vaccination series at age 65. She has never received a pneumococcal vaccination.

Vital signs today are within normal limits. Physical examination reveals crepitus in the right knee but is otherwise unremarkable.

Which of the following is the most appropriate next step in the preventive care of this patient?

Show answer & explanation

Answer: Administer the 20-valent pneumococcal conjugate vaccine (PCV20)

Answer

Administer the 20-valent pneumococcal conjugate vaccine (PCV20)
The patient is a 68-year-old woman who has never received a pneumococcal vaccine. According to the Advisory Committee on Immunization Practices (ACIP), adults aged 65 years and older who have not previously received a pneumococcal conjugate vaccine, or whose vaccination history is unknown, should receive either a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20) or a single dose of the 15-valent pneumococcal conjugate vaccine (PCV15) followed by a dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least one year later. Therefore, administering a single dose of PCV20 is an appropriate and guideline-concordant next step for this patient's preventive care.

Step-by-Step Solution

1
Identify the patient's age and vaccination history.
The patient is a 68-year-old adult who is pneumococcal vaccine-naïve.
Age 65 and older is a primary indication for routine pneumococcal vaccination regardless of underlying comorbidities.
2
Determine the appropriate pneumococcal vaccine regimen for this patient based on current ACIP guidelines.
The indicated regimen is a single dose of PCV20, or a dose of PCV15 followed by PPSV23 one year later.
Current guidelines have shifted away from using PPSV23 alone as the initial vaccine, favoring the broader coverage of the newer conjugate vaccines.
3
Evaluate the alternative preventive care options provided to rule out unnecessary interventions.
Abdominal ultrasound, carotid ultrasonography, and repeat DEXA scan are not indicated based on the patient's sex, smoking history, and prior normal screening results.
Adhering to evidence-based USPSTF guidelines prevents overdiagnosis and the harms of unnecessary testing.

Key Concept

Adults aged 65 and older without a history of pneumococcal vaccination should receive a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20) or the 15-valent conjugate vaccine (PCV15) followed by the 23-valent polysaccharide vaccine (PPSV23).
Estimated Time:1m 0s
Question 4559Question →

A physician is called to evaluate a hospitalized patient for sudden clinical deterioration. The 5353-year-old man was admitted 1414 days ago with severe biliary pancreatitis and has been managed supportively on the medical ward. Over the past 1212 hours, he has developed high fevers, worsening abdominal pain, and confusion. Vital signs show a temperature of 39.4∘C39.4^\circ\text{C} (102.9∘F102.9^\circ\text{F}), heart rate of 122/min122/\text{min}, respiratory rate of 24/min24/\text{min}, and blood pressure of 88/54 mmHg88/54\text{ mmHg}. His abdomen is diffusely tender and distended. Laboratory evaluation reveals a leukocyte count of 24,000/mm324,000/\text{mm}^3. The patient is transferred to the intensive care unit, fluid resuscitation is intensified, and intravenous meropenem is started. An urgent contrast-enhanced computed tomography scan of the abdomen demonstrates a large walled-off collection replacing the body and tail of the pancreas, comprising approximately 40%40\% of the gland. There are multiple distinct pockets of gas within this collection. What is the most appropriate next step in management?

Show answer & explanation

Answer: Image-guided percutaneous catheter drainage

Answer

The correct intervention is image-guided percutaneous catheter drainage, which serves as the first step in the minimally invasive management of infected pancreatic necrosis.
The patient has developed infected necrotizing pancreatitis, as evidenced by his clinical deterioration (fever, hypotension, leukocytosis) and the pathognomonic presence of gas within the pancreatic fluid collection on computed tomography. The established standard of care for infected necrosis is the 'step-up' approach. After initiating broad-spectrum intravenous antibiotics (e.g., meropenem), the most appropriate next step is minimally invasive source control. This is typically achieved through image-guided percutaneous catheter drainage or endoscopic transluminal drainage. By providing immediate decompression and drainage of the infected fluid, this minimally invasive first step significantly reduces the incidence of major systemic complications and mortality compared to primary open surgery.

Step-by-Step Solution

1
Identify the complication causing the patient's sudden clinical deterioration.
The presence of new-onset sepsis combined with computed tomography findings of gas within a pancreatic fluid collection confirms the diagnosis of infected necrotizing pancreatitis.
Gas-forming organisms within necrotic tissue are pathognomonic for infection and dictate an immediate shift from supportive care to active intervention.
2
Evaluate the patient's hemodynamic status to determine the urgency of intervention.
The patient is in distributive shock (hypotension, tachycardia) secondary to sepsis, necessitating prompt source control alongside ongoing medical resuscitation.
Intravenous antibiotics and fluids alone cannot penetrate and clear a large, walled-off infected necrotic collection.
3
Select the appropriate surgical or procedural intervention based on the modern 'step-up' approach.
Image-guided percutaneous catheter drainage (or endoscopic transluminal drainage) is selected as the initial procedure.
Clinical trials have established that minimally invasive drainage should precede surgical necrosectomy to minimize surgical trauma, morbidity, and mortality.

Key Concept

Infected necrotizing pancreatitis is managed using a step-up approach, which mandates broad-spectrum antibiotics and minimally invasive source control (e.g., percutaneous or endoscopic drainage) as the initial interventions before considering open surgical necrosectomy.
Estimated Time:1m 15s
Question 4560Question →

A 34-year-old man is brought to the emergency department by police due to severe agitation and aggressive behavior. He was found wandering in traffic, yelling at passing vehicles. In the emergency department, he is pacing rapidly, responding to internal stimuli, and attempting to strike staff members. He completely refuses to take any oral medications. His medical history is significant for schizophrenia, alcohol use disorder, and a recent hospital admission for an episode of syncope. Discharge records from that admission reveal a normal echocardiogram but a 12-lead ECG demonstrating sinus bradycardia with a corrected QT (QTc) interval of 540 ms540 \text{ ms}. Vital signs are temperature 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure 142/88 mmHg142/88 \text{ mmHg}, heart rate 94/min94\text{/min}, and respiratory rate 18/min18\text{/min}. Which of the following is the most appropriate initial pharmacologic intervention to manage this patient's acute agitation?

Show answer & explanation

Answer: Intramuscular lorazepam

Answer

Intramuscular lorazepam
This patient requires immediate chemical restraint due to severe agitation, aggressive behavior, and risk of harm to staff. However, his baseline QTc interval is 540 ms540 \text{ ms} (normal is typically <440 ms< 440 \text{ ms} in men), placing him at extreme risk for Torsades de pointes and sudden cardiac death if QTc-prolonging medications are administered. Benzodiazepines, such as intramuscular lorazepam, provide effective rapid sedation and have no effect on the QT interval. Therefore, lorazepam is the safest and most appropriate pharmacologic choice in this specific clinical scenario.

Step-by-Step Solution

1
Assess the clinical urgency and patient cooperation.
The patient requires immediate chemical restraint due to violence, and the intramuscular route is required because he refuses oral medications.
Ensures physical safety of the patient and staff while avoiding unfeasible delivery methods.
2
Review the patient's medical history for contraindications to standard therapies.
The patient has a documented baseline QTc interval of 540 ms.
Standard chemical restraints (antipsychotics) carry a risk of QTc prolongation and fatal arrhythmias.
3
Select an appropriate sedative agent that does not exacerbate the underlying cardiac risk.
Intramuscular lorazepam is chosen.
Benzodiazepines provide effective sedation for acute agitation without affecting ventricular repolarization (QT interval).

Key Concept

Management of acute agitation in patients with baseline prolonged QTc utilizing benzodiazepines to avoid fatal arrhythmias.
PreviousPage 228 / 237Next